This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Secretin / CCK-PZ test

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The secretin / cholecystokin-pancreozymin test may be used to assess pancreatic exocrine function. It is an invasive test and considerable skill is required to collect duodenal juice uncontaminated by gastric juice.

A double-lumen radio-opaque tube is passed following an overnight fast. One opening enables the collection of gastric secretions; the other, of duodenal secretions.

Three specimens of duodenal secretions are collected:

  • basal secretion
  • following intravenous secretin
  • following intravenous CCK-PZ

The volume, pH, amylase and bicarbonate contents of all samples are measured.

In the normal person:

  • secretin administration primarily stimulates bicarbonate secretion
  • cholecystokinin primarily stimulates pancreatic enzyme secretion

In cases of exocrine panceatic failure, bicarbonate secretion is lost early and enzyme secretion lost later.

Abnormal results are obtained in chronic pancreatitis, enzymic activity and bicarbonate falling before there is any obvious reduction in the volume of juice.

In pancreatic carcinoma, results may also be abnormal. A marked feature is a low volume of juice especially when the tumour is at the head of the pancreas producing obstruction.

Secretin may cause a paradoxical increase in gastrin levels if the patient has a gastrinoma.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.